MTD

Head of Process Analytics Gerry Keller reported a sale of 240 shares of Mettler-Toledo International Inc. (NYSE:MTD) on August 3, following a derivative exercise, according to a recent SEC Form 4 filing. Transaction value based on SEC Form 4 weighted average sale price ($1,427.14); post-transaction value based on the August 3 market close ($1,445.00). What were the structural mechanics of this transaction?The transaction was a same-day exercise and sale, where Keller converted 240 derivative instruments into common stock at a strike price of $720.81 before liquidating them on the open market. The underlying options were part of a grant that vested annually in five equal installments. What is the executive's remaining equity exposure?At the conclusion of this transaction, Keller maintains direct ownership of 259 shares with a market value of $374,255.00 based on the August 3 closing price, supplemented by 235 derivative securities. This represents an aggregate insider ownership stake of just 0.0013% in the company. How has the stock performed leading into this disposition?Mettler-Toledo International shares achieved a one-year total return of about 20% as of the August 3 transaction date. As of the August 4 market close, shares were priced at $1,437.00. What is the current financial scale of the company?The Columbus-based enterprise reported trailing 12-month revenue of $4.1 billion and net income of $905.6 million. With a market capitalization of $29.0 billion, the company operates across five geographical divisions serving global scientific and industrial precision instrument markets. Mettler-Toledo International Inc. manufactures and distributes precision instruments and related services for laboratory, analytical, and industrial applications, generating revenue across its diversified product portfolio that serves scientific research, quality assurance, and process control functions globally. The company operates a geographically diversified business model with five regional divisions spanning the United States, Switzerland, Western Europe, China, and other international markets, enabling localized service delivery and market penetration across developed and emerging economies. The company serves a broad customer base, including pharmaceutical manufacturers, chemical producers, academic research institutions, food and beverage processors, and industrial enterprises that require precision measurement and analytical solutions for quality control and research applications. Mettler-Toledo International Inc. is a global leader in precision instrumentation with a market capitalization of $29.0 billion and TTM revenues of $4.1 billion, demonstrating substantial scale in the medical diagnostics and research sector. The company's strategic geographic diversification and comprehensive product portfolio position it to capture growth opportunities across multiple end markets while maintaining operational efficiency through regional manufacturing and distribution networks. With TTM net income of $905.6 million, the company demonstrates strong profitability and operational leverage in its core precision measurement and analytical instrumentation business. What stands out here is how little stock Keller holds to begin with, roughly 500 shares once this sale settles, so this appears to be an executive who exercises options and largely sells as they vest rather than building a large position, which would make the filing routine by habit rather than a fresh decision. The shares came from options struck at $720.81 and sold near $1,445, a healthy gain on equity granted years ago, cashed in days after the company reported a strong quarter.Mettler-Toledo grew organic sales by about 4% last quarter, ahead of guidance, and lifted adjusted earnings 14% to $11.46 a share, with China up 9% on double-digit industrial demand tied to onshoring and areas like battery production. CEO Patrick Kaltenbach called the China result "a very strong result versus the guidance we initially had." The pull toward reshored manufacturing and newer industrial segments is an important thread to watch, since those are the trends feeding the process and industrial demand that carried the quarter, and that’s ultimately what long-term investors should be more focused on with this stock. Before you buy stock in Mettler-Toledo International, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Mettler-Toledo International wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $399,832!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,374,595!* Now, it’s worth noting Stock Advisor’s total average return is 968% — a market-crushing outperformance compared to 215% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of August 10, 2026. Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. What Investors Should Know as Mettler-Toledo Insiders Sell Shares After a Strong Quarter was originally published by The Motley Fool

Shawn Vadala, the chief financial officer of Mettler-Toledo International Inc. (NYSE:MTD), executed a sale of 2,240 shares on August 3, according to an SEC Form 4 filing. Transaction value based on SEC Form 4 weighted average sale price ($1,432); post-transaction value based on the August 3 market close ($1445). What were the mechanics of this transaction?The sale was a non-discretionary liquidation of equity following the exercise of 2,240 stock options that were granted with a five-year annual vesting schedule. How does the execution price compare to the market valuation?The shares were sold at $1,432 per share, while the stock was priced at $1,445 at the August 3 market close; the company has recorded a close to 20% gain over the one-year period ending on the transaction date. What is the insider's remaining financial interest in the firm?Following this transaction, Shawn Vadala retains a direct ownership stake of 0.03% in the company, which carries a market capitalization of $29.0 billion. What is the company's current financial profile?Mettler-Toledo International reported trailing twelve-month revenue of $4.1 billion and net income of $905.6 million as of the August 4 market close. Mettler-Toledo International Inc. manufactures and distributes precision instruments and related services for laboratory, analytical, and industrial applications, generating revenue across its diversified product portfolio that serves scientific research, quality assurance, and process control functions globally. The company operates a geographically diversified business model with five regional divisions spanning the United States, Switzerland, Western Europe, China, and other international markets, enabling localized service delivery and market penetration across developed and emerging economies. The company serves a broad customer base, including pharmaceutical manufacturers, chemical producers, academic research institutions, food and beverage processors, and industrial enterprises that require precision measurement and analytical solutions for quality control and research applications. Mettler-Toledo International Inc. is a global leader in precision instrumentation with a market capitalization of $29 billion and TTM revenues of $4.1 billion, demonstrating substantial scale in the medical diagnostics and research sector. The company's strategic geographic diversification and comprehensive product portfolio position it to capture growth opportunities across multiple end markets while maintaining operational efficiency through regional manufacturing and distribution networks. With TTM net income of $905.6 million, the company demonstrates strong profitability and operational leverage in its core precision measurement and analytical instrumentation business. Vadala exercised options and sold the resulting shares just days after Mettler-Toledo delivered a beat-and-raise quarter, converting a portion of a five-year grant into cash while the stock traded near $1,440, a high share price reflecting a company that has never split its stock. He sold a touch below the day's close and remains a small fractional owner, so this is a finance chief effectively harvesting a maturing grant into strength, not a signal about what comes next.The quarter he sold into was strong. Mettler-Toledo grew second-quarter revenue by about 4% to just over $1 billion and lifted adjusted earnings 14% to $11.46 a share, thanks in large part to strong China sales. One number to keep in view is that gross margin got a lift from a one-time $52.4 million tariff refund, so the underlying margin was not quite as strong as the headline, and that boost will not repeat next quarter, but ultimately, the company raised its full-year outlook, and CEO Patrick Kaltenbach pointed to "better-than-expected organic sales growth across our portfolio." Before you buy stock in Mettler-Toledo International, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Mettler-Toledo International wasn’t one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $399,832!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,374,595!* That performance is why people listen. With a track record of beating the S&P 500 by 4x, Stock Advisor offers a distinct advantage. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built for the long haul. See the 10 stocks » *Stock Advisor returns as of August 10, 2026. Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Mettler-Toledo's CFO Cashed In Options After a Strong Quarter. Here's What to Know was originally published by The Motley Fool

Image source: The Motley Fool. Friday, Jul. 31, 2026 at 7:30 a.m. ET Head of Investor Relations - Adam Uhlman Chief Executive Officer - Patrick Kaltenbach Chief Financial Officer - Shawn Vadala Operator: Hello, everyone. Thank you for joining us, and welcome to the Mettler-Toledo Second Quarter 2026 Earnings Conference Call. [Operator Instructions] I will now hand the conference over to Adam Uhlman, Head of Investor Relations. Please go ahead. Adam Uhlman: Great, Jonathan. Thank you very much, and good morning, everyone. Thanks for joining us. On the call with me today is Patrick Kaltenbach, our Chief Executive Officer; and Shawn Vadala, our Chief Financial Officer. Let me cover some administrative matters. This call is being webcast and is available for replay on our website at mt.com. A copy of the press release and the presentation that we will refer to on today's call is also available on our website. This call will include forward-looking statements within the meaning of the U.S. Securities Act of 1933 and the U.S. Securities Exchange Act of 1934. These statements involve risks, uncertainties and other factors that may cause our actual results, financial condition, performance and achievements to be materially different from those expressed or implied by any forward-looking statements. For a discussion of these risks and uncertainties, see our recent annual report on Form 10-K and quarterly and current reports filed with the SEC. The company disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statements, except as required by law. On today's call, we will use non-GAAP financial measures and a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measure is provided in the 8-K and is available on our website. Let me now turn the call over to Patrick. Patrick Kaltenbach: Thank you, Adam, and good morning, everyone. We appreciate you joining our call today. Last night, we reported our second quarter financial results, the details of which are outlined for you on Page 3 of our presentation. Our second quarter results were strong and reflected better-than-expected organic sales growth across our portfolio, including very good growth in China and emerging markets. It was driven by improved market conditions and our focused Spinnaker sales and marketing program. Combined with our productivity initiatives, this resulted in excellent adjusted EPS growth in the quarter. Going forward, we are optimistic market conditions will gradually improve. Our team remains agile and focused on capturing growth opportunities, leveraging our sophisticated Spinnaker program and innovative product portfolio while benefiting from trends in automation, digitalization and onshoring investments. I am confident that strong execution of our strategic initiatives will continue to deliver solid financial performance. Let me now turn the call over to Shawn to cover the financial results and our guidance, and then I will come back with some additional commentary on the business and our outlook. Shawn? Shawn Vadala: Thanks, Patrick, and good morning, everyone. Before I review our Q2 results, I'd like to highlight a special item in our financials this quarter related to tariffs. As disclosed last quarter, we had a one-time gross benefit of $52 million from IEEPA tariff refunds in Q2 that benefited cost of sales, and was offset in part by a $28 million related refund to our customers that reduced our reported net sales by 3%. Discussion of our results today will exclude the impact of both of these items. Sales in the quarter were $1 billion, up 7% in U.S. dollars. And in local currency, our growth was 6% and above our price -- our prior guidance of approximately 3% local currency sales growth. Acquisitions contributed approximately 1.5% to sales growth and organic local currency sales growth was 4%. On Slide #4, we show sales growth by region. Organic sales, excluding acquisition and tariff refunds, increased 1% in the Americas, 4% in Europe and 9% in Asia/Rest of World, including 9% growth in China. Slide #5 shows core organic sales growth by region on a year-to-date basis. On Slide #6, we summarize sales growth by product area. Organic sales increased 4% in Laboratory and increased 3% in Industrial, which included 4% growth in Core Industrial and 1% growth in Product Inspection. Food Retail grew 11% in the quarter. Lastly, service revenue grew 9% or 7% organically. Slide #7 details organic sales growth by product area on a year-to-date basis. Let me now move to the rest of the P&L, which is summarized on Slide #8. Adjusted gross margin was 59.3% in the quarter, an increase of 30 basis points. Excluding unfavorable foreign currency and acquisitions, gross margin expanded approximately 90 basis points due to benefits from favorable price realization, lower tariff rates compared to the prior year, volume growth in our productivity and cost savings initiatives, partly offset by higher transportation costs. R&D amounted to $53 million in the quarter and was up 3% on a local currency basis over the prior period. SG&A amounted to $263 million a 4% increase in local currency over the prior year and includes sales and marketing investments, offset in part by cost savings. Adjusted operating profit amounted to $309 million in the quarter, up 9% versus the prior year. Adjusted operating margin was 29.3%, an increase of 50 basis points versus the prior year or up 100 basis points excluding unfavorable currency. Adjusted EPS for the quarter was $11.46, a 14% increase over the prior year. On a reported basis in the quarter, EPS was $11.55 as compared to $9.76 in the prior year. Reported EPS in the quarter included a $0.92 net tariff refund benefit, $0.26 of purchased intangible amortization, $0.22 of restructuring costs and a $0.04 tax headwind related to the timing of stock option exercises. Finally, we had a $0.31 acquisition-related charge related to higher earn-out achievements on previous acquisitions. That covers the P&L, and let me now comment on adjusted free cash flow, which amounted to $367 million on a year-to-date basis and was negatively impacted by the timing of tax payments, which were $55 million higher than the prior year. DSO was 35.6 days, while ITO was 4.2x. Let me now turn to our guidance for the third quarter and the full year 2026. As you review our guidance, please keep in mind the following factors. First, we are encouraged by our Q2 results and improved market conditions, especially in China and emerging markets. Second, conditions in the Middle East remain volatile. And while we have limited exposure to the region, this could impact customer decision-making should conditions significantly change. We are not currently seeing any change in related customer behavior and have not included an escalation of the conflict in our forecast. Lastly, we are very confident in our ability to execute on our growth and productivity initiatives and believe we are well positioned to gain market share regardless of the macro environment. Now turning to our guidance for the full year 2026. We have increased our local currency sales growth from approximately 4% to approximately 4% to 5%, reflecting organic growth of 3% to 4%. Our forecast excludes the impact of the previously described tariff refunds. Adjusted EPS for the year is forecast to be in the range of $47.15 to $47.50, which represents a growth rate of 10% to 11% or 11% to 12%, excluding currency. This reflects an increase from our previous guidance of 8% to 10% growth. At recent spot rates, foreign currency is estimated to be a 1% benefit to sales growth and a slight headwind to EPS for the year. For the third quarter of 2026, we expect local currency sales to grow approximately 4%, which includes approximately 0.5% benefit from acquisitions. We expect adjusted EPS to be in the range of $12 to $12.15, a growth rate of 8% to 9% or 9% to 10%, excluding currency. Currency for the quarter at recent spot rates would be neutral to third quarter sales and a 1% headwind to adjusted EPS. Some further comments on our 2026 guidance. We expect total amortization, including purchase intangible amortization to be approximately $78 million. Purchased intangible amortization is excluded from adjusted EPS and is estimated at $28 million on a pretax basis or approximately $1.07. Interest expense is forecast at $67 million for the year. Other income is estimated at approximately $24 million. We expect our tax rate before discrete items will remain at 19% in 2026. Free cash flow is expected to be approximately $900 million in 2026, which represents 6% growth on a per share basis. Share repurchases are now expected to increase to $875 million for the full year as compared to our annualized repurchase level of $825 million during the first half of the year. That's it from my side, and I'll now turn it back to Patrick. Patrick Kaltenbach: Thanks, Shawn. Let me start with some comments on our operating businesses, starting with Lab, which had good growth in the quarter across most product areas. We saw improving trends across our biopharma customer base and continue to see strong growth in process analytics and bioproduction. Laboratory balances and analytical instruments growth was also strong and benefited from the many innovations we have brought to the market in the recent years, our LabX software and growing demand from hot segments like semiconductor, advanced materials and batteries. Turning to industrial. Core Industrial did well this quarter with sales growth driven by strong demand for our solutions that enable automation. We saw strength across markets like biopharma, food manufacturing, semiconductor and new energy. As expected, Product Inspection organic sales growth this quarter was modest due to the timing of customer projects, but organic growth is expected to pick up again in the second half. Lastly, food retail sales growth was better than expected due to the timing of project activity. Now let me make some additional comments by geography. Starting in the Americas, where sales grew 1%, excluding acquisitions. We had strong momentum in most Lab product categories and in our Core Industrial Automation Solutions and Product Inspection. These results were offset in part by timing of food retail and transportation and logistics project activity. Turning to Europe. Sales growth this quarter was solid and included growth across most of the business, including strong growth in Core Industrial and food retail. Finally, Asia/Rest of the World had very good growth this quarter across the portfolio and in most major markets. Our business in China grew 9% and was stronger than expected as our team continues to do an excellent job identifying high-growth markets and leveraging our innovative portfolio. Biopharma customers' demand was also healthy and contributed to our results. Markets outside of China also had strong growth this quarter. Emerging markets have been an important element of our long-term growth strategy for many years. India, Southeast Asia, Eastern Europe and Latin America offers excellent growth opportunities as these markets develop and mature, and we believe many of them will also benefit from near-shoring investments over the coming years. Our company is uniquely positioned to capitalize on emerging market growth over the coming years. In the second quarter, emerging markets outside of China represented approximately 18% of our sales, slightly more than our business in China and grew high single digits in the quarter. Emerging markets, excluding China, have also grown high single digits on average in local currencies over the last 5 years, above the company average and are an important contributor to our growth. To take advantage of these growth opportunities, we have long-standing dedicated market organizations in emerging markets, China and around the world. Our market organizations are a significant competitive advantage, allowing us to stay close to customers and better understand local market needs. We have dedicated growth plans for each major country and we leverage our broad portfolio of solutions across a range of price and value points to meet varying customer requirements. Additionally, in markets like Mexico, we have further developed local assembly and manufacturing capabilities in recent years, which strengthen our ability to serve local market needs and enhance our competitive position. The market organizations and emerging economies also leverage the same Spinnaker sales and marketing programs we have developed in other countries, including various digital tools, value selling guides and sales enablement tools. We have also rolled out Blue Ocean to most of our MOs and having a single instance of a global information technology infrastructure provides rich data, analytics and unique real-time business insights. This is a significant competitive advantage that allows us to target opportunities in various hot segments like bioprocessing, GLP-1s, semiconductor and battery in an agile way. As domestic and foreign direct investments continues to grow over the coming years, we expect emerging markets to remain a healthy contributor to our growth well into the future. In summary, we are very pleased with our Q2 results and the solid growth our team has delivered. We remain focused on capitalizing on our customers' investments in automation, digitalization and onshoring around the world. After a few years of disruptions and uncertainties related to tariffs, governmental policies and geopolitics, we believe customers will continue to return to a more normal replacement activity going forward. We have maintained a strong focus on investing in innovation and growth in recent years while protecting profitability, which will serve us well as our markets recover. This concludes our prepared remarks. Operator, I'd now like to open the line to questions. Daniel Arias: Shawn or Patrick, last quarter, you raised the guide for China. So I guess not a surprise to see the pickup there, but it does seem like maybe it improved a bit sooner. Can you just dive into the acceleration a bit? What does the momentum there look like when it comes to pharma versus non-pharma and just sort of the consistency that you expect in the coming quarters? If I remember correctly, the improvement seemed like it was due more to core industrial last quarter. So to what extent do you have pharma improvement sort of baked into the outlook for the rest of the year here? Patrick Kaltenbach: Yes. Thank you, Dan. And yes, of course, we are very happy with the growth we have seen in China, 9% in Q2 was really a very strong result versus the guidance we initially had for the quarter. I mean the growth has really been led by Industrial, which had double-digit growth in China. We are benefiting from many of the core segments such as biopharma, but also food as well as the hot segments like investments in battery that is happening in China. For Lab, the growth was a bit more modest. We expect continued improvement there also in the second half, both also from biopharma and maybe also academia will pick up towards the end of the year. We see or we had at least some indications of some additional funding for academia in China as well. But then again, also the good hot segments and the strong investments in areas like lithium battery and new energy. So overall, I would say, really led by industrial, the growth across many segments and pharma was a good part of that as well. Shawn Vadala: Yes. Dan, then just to be specific, like in terms of the second half of the year, we're looking at high single digit now for China also for Q3 and for the full year. And we kind of -- this momentum that Patrick referred to on industrial, we feel very good about entering the second half. Also the trends around automation and digitalization that we talk a lot about, we're definitely seeing those benefits in China as well. And then I think as we kind of go into the second half of the year, too, we also feel like that the Lab business is gradually improving as well. Daniel Arias: Yes. Okay. And then maybe just on product inspection. A little bit of growth in that piece. I think you had been pointing to that being down a touch this quarter on some timing elements that you referred to. Can you just maybe expand on that? Was there anything that got pulled forward from 3Q as it relates to that timing? And then if you put the timing aspect aside, maybe just talk about spending and demand relative to the way that you saw things last quarter in PI specifically. Shawn Vadala: Yes. No, thanks, Dan. So if you remember, we had a really good Q1 in PI, and then we were trying to caution people that Q2 would be a little bit lighter just given the timing of how the project activity was looking like it was playing out. But as we kind of like go into the second half of the year, I mean, we feel very good. I mean, we're probably looking at mid-single-digit growth in the third quarter. And for the full year, we're probably looking at high single-digit growth, which is probably more like mid-single-digit growth on an organic basis. But when you step back, 70% of that business is food manufacturing. So the -- from an end market perspective, not quite like pharma. But when we look at how the team is executing, we actually feel really good. I mean we talked a lot about the benefits of innovation in this business over the last few years, and we kind of continue to see that. We're coming out with a couple of new products this year, which is pretty exciting. And then this general strategy that we've talked a lot about in terms of how to better position ourselves for the mid-market segment seems to be working very well and well received in the marketplace. Tycho Peterson: Just wanted to maybe unpack some of the other trends from 2Q. I guess as we think about the revised guide in the back half of the year, can you just talk a little bit more about some of the underlying assumptions by end market and segment? Obviously, you just covered PI in China, but maybe walk through where you're changing your assumptions otherwise. Shawn Vadala: Yes. Tycho, I'll take that one. Thank you. So I'll start with the product categories, and then I'll give you the division. So Lab for Q3 would be mid-single digit. Core Industrial, we're looking at low single digit. And I think it's important to remember that Core Industrial had a very challenging comparison to the prior year in Q3 of last year. It grew 10% organically. Product Inspection, mid-single digit, which I just said, and then Retail, we're guiding at flat. In terms of the Americas, we're guiding at low to mid-single digit. Again, this one had a more challenging comparison, just to highlight in Q3 of last year, which was up, I think, 9% organically. Europe, up low single digit. China, we talked about high single digit. And then maybe just to kind of wrap it up with the full year. Full year Lab would be low to mid-single digit. Core Industrial would be low to mid-single digit. Product Inspection would be high single digit. And of course, there's a little bit of acquisition from the -- largely from the first half of the year in these numbers. So Core Industrial would be low single digit organically. PI would be mid-single digit. Retail would be low to mid-single digit. And if we look at the regions, Americas would be low single digit or about flattish organically. Europe would be low single digit and then China would be high single digit. Tycho Peterson: Okay. Very helpful. And then a follow-up, you've guided 2.5% on price for 2Q. Just curious where you landed and what you're thinking for the back half of the year? And then separately, did you capture -- recapture any of the delayed chemical orders? Shawn Vadala: Yes, sure. So on the pricing side, continue to be really pleased with the team's execution. But ultimately, pricing comes back to value proposition. I think a lot of the investments we've been making over the last few years on innovation continue to pay off well. So in the end, our price realization for the quarter was around 3%. So we're very happy with that. So a little bit better than the 2.5% that you were mentioning in terms of our original guidance. Towards the end of the quarter, we also put in place some additional pricing measures isolated in a few areas where we were seeing a little bit of inflationary pressures. So our guidance for the second half of the year is more in the 2.5% kind of a range. And again, we're -- as a reminder, we're also lapping a lot of the midyear price increase actions that we did last year in response to all the tariffs from last year. So when you kind of wrap that all up, our full year price realization is now approaching 3% for the full year. I think the other part of your question was China -- I mean, not China, Chemical, Europe, do you want to take that one or... Patrick Kaltenbach: I can take that one. Tycho, so yes, on chemical, just as a reminder, I mean, overall, it's under 15% of our total sales, and we had probably the biggest exposure across Industrial and Lab for chemical. It's -- for us, it's mostly specialty chemicals. And when we talked in Q1 about the pressures we have seen in the EU, it was mainly energy related. It's our view on things. Actually, the EU chemical results were better in Q2, so they recovered. And -- but we still would say we take a bit more cautious stance on the overall segment still because they are more exposed to energy cost fluctuations than other segments that we're seeing. And -- but overall, of course, in the quarters to come, we will also have easier comps in the segment. Joshua Waldman: I think one for Patrick and one for Shawn. Patrick, nice to see the reacceleration in Lab. I guess, can you give more details on what drove this? It would be great to get a sense on what you're hearing from customers on the why behind the inflection in the second quarter following what would seem to be a softer start to the year. Was it budgets being delayed, concern around the war or other? And then as you think about durability kind of going forward, the comps get more difficult, but it sounds like you're expecting mid-singles again in the third quarter. Do you think Lab kind of should stay in the steady state of mid-single digits here as we work through the second half and maybe into '27? Patrick Kaltenbach: Yes. We will not talk -- thanks, Josh. We will not talk about '27 yet. But of course, we are actually quite delighted with how Lab is performing. And a lot of that is based not only on our strong go-to-market strategy and our local market teams that we have that are really very close to our customers. I think it's also based on the fact that we have really put a lot of effort into innovation over the last years. We launched a lot of new great products across the Lab portfolio. And within Lab, at the moment, of course, the process analytics business is performing extremely well in biopharma, as you can imagine. So that drives a lot of the growth as well. And then you look at the rest of the portfolio that we have, analytical instruments have been very good in Q2, and we see that also moving forward. We saw the pipette business coming back to growth as well last quarter, which is very promising. So I would say, yes, we're actually quite pleased with the momentum we have in Lab moving forward. We do expect, as Shawn said, for Lab mid-single digits growth about that range. And it's pretty broad-based. I think if there is even some upside to this, it would be potentially an acceleration in China that still has to materialize. Again, we saw some initial good momentum, but that was more in Industrial in China, and I think Lab is more to come. Overall, extremely well positioned for lab products with our LabX software platform. As you know, we provide about 40% of the instruments that are used typically in the QA/QC lab and most of them are connected to our LabX portfolio, which gives our customers a really unique opportunity to do just their testing in a very compliant way and using LabX as a complete workflow control system and also aggregate the data to use AI on the next level if they want to. So it's -- I think we are very pleased with where we are with Lab, and I think there's more to come. Thank you. Joshua Waldman: Yes. Good to hear. Okay. And then, Shawn, can you give an update on how margins are tracking versus your plan? Any updated view on the full year margin expectation? I mean it seems like you're tracking ahead of plan. Is this reflecting moving pieces on the tariff refunds? Or are there other drivers you'd highlight? Shawn Vadala: Yes. So just to be clear, the tariff refund topic is excluded from our results, our adjusted results and our guidance. Now of course, changes in tariff rates is a different story. And so that can be a factor here. But we feel very good about the team's execution. We really -- I think we've been trying to like really focus on this always in the past. I think if you look at the different initiatives that we have kind of underlying margin expansion like the SternDrive program, productivity programs, cost savings initiatives, they're all, I think, very important. And I think it definitely highlights, I think, some of the culture in the company as well. If we look at Q2, you kind of heard we -- if you look at the operating margin, we were up like 100 basis points if you exclude currency. If you look at that from a full year perspective in terms of what we're thinking for 2026, we'll probably be, excluding currency, probably up 60, 70 basis points, maybe modestly better than what we were thinking before. Now there's some currency in that. So on a reported basis or not excluding currency, it would be up slightly, maybe in the 10 to 20 basis point kind of range. And that's at the operating margin level, yes. Vijay Kumar: I guess, Shawn, my first one, a quick housekeeping. What was FX in M&A contribution in the quarter? Shawn Vadala: Yes, it was about -- so in terms of -- you're talking -- I'm sorry, Vijay, you said -- did you say FX in M&A in terms of revenue? Vijay Kumar: Foreign exchange... Shawn Vadala: Yes, yes. So I usually don't think in terms of foreign exchange. So the acquisition contribution was about 1.5%. And then in terms of FX, I think if you kind of like look at our reported numbers versus our local currency, it implies 1%. But I think with rounding, it's north of 1%. Vijay Kumar: That's helpful. And I guess when I look at the updated guidance, Shawn, when you do the math, I think the implied exit rate for Q4 is somewhere between 4% to 5%, depending on the midpoint or high end of the guidance. That's a step-up, right? That's a sequential step-up from 3Q. I know in the past, you've spoken about the backlog and order visibility, right? Is that what's driving the sequential step-up? Like what gives the confidence in this fourth quarter exit rate? Shawn Vadala: Yes. So I think -- so Vijay, a couple of things. So first of all, I think if you look at it from a growth perspective, yes, the implied Q4 is a little bit higher than the Q3 guidance. I think a lot of that also has to do with the fact that Q3 has a much more challenging comparison to the prior year. I kind of called out a little bit the industrial business as an example, and also the Americas had a challenging comp. So I think that's kind of part of it. But I think if you also just look at sequentials in terms of just like the flow of quarters and dollars from one quarter to another, I feel like the sequentials are pretty in line with historical sequentials. And then as we kind of like exit the year, we feel like we have some good momentum entering into the back half of the year. And I think, yes, when you look at what we're seeing in the business today, we definitely feel good about the momentum that we're kind of carrying into the second half. Michael Ryskin: Maybe I want to dig a little bit more into biopharma. It sounds like that's one of the places you're feeling a little bit better this quarter. I had some comments on bioprocess analytics, bioproduction balances. Just would love to expand more on that. Did you see -- was it sort of like -- how big of a step-up was it? Was it above your expectations? Anything about where you're seeing that momentum the most and just expectations for that going forward? Do you feel like you're early on? Or you've already sort of like crested it, if you know what I mean? Patrick Kaltenbach: Yes. Thanks, Mike. I'll take that question. Look, let's talk about biopharma and bioprocessing here. I'll start with bioprocessing, which is overall, I think, a low double digit of our total sales. It's mostly Pro, but also part of the Industrial Automation portfolio plays here. Pro had really good growth again in Q2, especially in the Americas with bioprocessing. And there's also some good equipment demand from industrial coming on from these automation providers where we serve them with our automation solution equipment from industrial products that we have. So there's really good momentum there. When you ask about the investments in pharma and biopharma, you're probably referring here to the reshoring activities, I guess. We -- I think we are -- number one, we are extremely well positioned for that because about 50% of our sales go into production, plus about 20% QA/QC, where we cover a lot of the value chain there. And we are in an excellent position with our biopharma portfolio, but also helping on the industrial automation portfolio. We see some good activities, some RFQs here related to reshoring, but I still would say it's early innings. I think this momentum will continue to pick up in the second half and also as we go into 2027. But yes, there are some activities and you probably all have heard about companies expanding their manufacturing in the U.S. I think until then, there will be really some groundbreaking of additional facilities that will still take some time, and then there will be more investment coming in the years '27 and '28. For now, again, most of what we see is facility investments and capacity expansion in the U.S. Shawn Vadala: Yes. Another interesting dynamic, too, is like there's been a lot of questions and talk about replacement cycles. And if you just look at our results in Q2 and one quarter doesn't necessarily make a trend, but it was encouraging to see very strong growth in the analytical instrument business as well as laboratory balances. And if you think about the types of instruments that are typically on a QA/QC bench, those categories actually did very well in the quarter here. Michael Ryskin: Okay. Okay. And then maybe just going back to what Vijay was just asking about in terms of the second half outlook. Yes, as you just touched on in that answer, you do have a little bit of a step-up. But you also talked about in your prepared remarks expectations for Middle East and geopolitics and the macro and all that. It sounds like you're not expecting -- you're kind of expecting status quo for that. I guess what I'm trying to get at is, it feels like you did get bit by that a little bit in the first quarter. So I just kind of want to get at how much buffer there is in the guide if things do escalate, just maybe a degree of conservatism or areas of upside potentially to offset if the macro Middle East gets a little bit worse, just sort of a repeat of what happened in 1Q. Shawn Vadala: Yes. Mike, maybe I'll take that one and Patrick can add some color if you'd like. But I think there's a little bit of a difference right now. I think one is like there is very strong momentum that we're seeing in terms of customer activity. And so we feel very good about how we're sitting to the second half. Now we always acknowledge we're pretty short cycle with 1.5 months of backlog. But when we look at everything holistically, we actually feel good, and we start to lap also some topics from a year ago like academia and biotech, which are smaller end markets in general, but we feel like some of these end markets are starting to improve. We're starting to see growth again in the pipetting, liquid handling business, which has also been really good. It's been a headwind for a while for us. If you look at like the Q1 dynamic, like you mentioned, absolutely. And I think one of the issues there was that we had expected companies to maybe start the year slow. I think with all the uncertainty that was hitting companies right at the beginning of the year, one of the things we kind of felt was that a lot of customers were holding off on finalizing budget commitments within their organization. So a lot of things were also getting held up as kind of like a generic statement. Right now, it seems like people have their budgets. They know what they want to do. There are the projects. And while things can always change, we feel like there's pretty good momentum going into the second half of the year. And then I think we'll learn a lot more about what it means over the next 3 months, and it might be more of a question on what it could mean for 2027. But I think the reality is that there's a lot of dynamic topics going on always in the world, and we'll continue to monitor them. But regardless of the environment, I feel like the team is trying to stay focused on what we can control and executing well. Jack Meehan: I had a couple of follow-up guidance questions for you. The first is, so if I just look at EPS, you beat the second quarter by about $0.70 and the midpoint of guidance is going up by $0.70. So it seems like a lot of the raise is related to what you saw in the second quarter. So just trying to square that with your comment that overall, it seems like conditions are improving. Just is that conservatism? Or are there other offsets that you're building in at this point? Shawn Vadala: Yes. I think it's fair, Jack. I mean I think if you kind of like look at how we're -- how the second half -- like very happy with our Q2 results, of course, very happy to raise guidance for the full year, very happy with the momentum we're seeing in the business, acknowledge if you're trying to look at what your second half model looks like today versus 3 months ago. It looks like maybe there's a little bit of conservatism or moderation slightly. It's not reflecting anything we're seeing in the business, but we feel like maybe that kind of derisks any concerns out there for any of the geopolitical stuff, and we feel generally pretty good as we kind of go into the second half of the year. Jack Meehan: Great. And then I wanted to poke a little bit more at the Core Industrial business. You talked about chemicals a bit. I'm actually not sure if some of that overlaps in the Lab, but we now have 6 months in a row of U.S. manufacturing PMIs over 50. So felt like we might see a little bit more momentum there. I was wondering if you could just talk about more like the macro sensitive stuff, like if you think there's still some of that correlation or if there's a reason why maybe it diverges for some reason? Shawn Vadala: Yes. No, it's a good question because if you kind of look at -- well, first of all, there's a couple of different things. The one thing that isn't necessarily evident in the results until you like look internally and unpack them is like the categories that are really supporting automation and digitalization around the world are actually growing very well, and we see that. We also -- while we're less correlated to PMIs than we were 10 years ago, we also recognize that when the economy does better, we generally should do better as well, too. And even though there's a little bit of a delay. But the one thing that maybe doesn't jump out is that within Industrial, there can be small pockets of project activity. And one of those pockets is our transportation and logistics business. And the reality is there's just like some timing going on with larger customer projects, and that's kind of like mitigating some of the other positive results you're seeing in that business. But overall, we feel actually quite good. And if you kind of like look at even our Q3 guide, despite lapping also some pretty large comps in industrial as well as the Americas from a year ago, we actually feel pretty good about our guidance and how the outlook is for the second half. Casey Woodring: Now that we're in the back half of the year, curious just how reshoring conversations have trended, if those have picked up at all? And if you would expect orders to roll through here before the year-end? Patrick Kaltenbach: Yes. Casey, I mean I think I partly at least addressed it in one of my former answers. Yes, we see some activity there with RFQs that are related to reshoring, again, as customers are expanding manufacturing in the United States, that is a good indication that there's more business to come. Again, the larger factories and investments still have to be made. So they are still early innings. But we see -- we truly see the pharma, biopharma investments as largely incremental for us moving forward when you think about biopharma CapEx plans, especially when it comes to instrumentation, think about the tank scale, think about the QA/QC lab. So there will be moving forward, some good momentum. And we are, of course, in a lot of discussions with some of our key customers there about their plans. And it's still early innings, but yes, the momentum has picked up, and we are pretty positive that this will carry well into 2027, 2028. Casey Woodring: Got it. That's helpful. And then, Patrick, can you just walk through how performance trended in the Americas by business segment and end market? Curious on how things like academia and government and biotech trended, right? Like you mentioned pipetting returned to growth. So within that 1% organic number in Americas, I would just be curious to hear what drove that and maybe what's still lagging and how you would see that region playing out in the back half? Patrick Kaltenbach: Maybe, Shawn, you can repeat again how you guided Americas for Q3 and for fiscal year. Shawn Vadala: Yes. So the Americas, the guide for Q3 is low to mid-single digit. But again, we're lapping 9% in the prior year. And if you kind of like look at the different end markets, I don't know, Patrick, if you want to contribute here, but I can kind of run with it if you want, like in terms of like the end markets, we're certainly seeing improvement in some of the areas that have been softer like academia or biotech. And our pipetting business is a good example of that. It's larger exposures for that business, smaller for the Americas overall. So that feels pretty good. Bioprocessing has been a very hot segment in the U.S. for us. A lot of the different like hot segments as well like process analytics particularly benefits from like power, semiconductor are also doing very well. And then if you think about like these trends around industrial automation, digitalization, good momentum there, as I mentioned. And like Patrick said, onshoring, we're well positioned for it, but still probably very early innings there. And then what was also nice is just like I kind of commented on earlier about like if you think about the value chain, that QA/QC space where like analytical instrumentation, like that was a nice -- that was good momentum also in the quarter. So I think kind of like the setup, the trends continue to, I think, go generally in a good direction. We do get lumpiness from time to time from things like retail. But if you kind of look beyond that, the underlying business looks positive today. Kallum Titchmarsh: Maybe just following up on Tycho's question on price. Could you maybe just break out a bit more specifically which segments and geographies you've been more aggressive with on price just as we think about performance in the quarter? And then obviously, that 2%, I believe, is the long-term assumption for price. But just given the uptick in end market health and some of the innovation you've spoken to, any reason why that couldn't sit above 2% when we think about 2027 and beyond? Shawn Vadala: Yes. We'll talk probably more about those types of assumptions at our upcoming Analyst Day, but I certainly wouldn't expect us to come out with a higher price increase guidance than 2%. We feel pretty good about that one for the long term. In terms of breaking it down, Kallum, we typically wouldn't get into too much detail, but maybe a good way to think about it is that we tend to do well in most geographies in the world. And -- but geographies where there's higher inflationary pressures are going to have higher price increases. And so for example, like in the United States, of course, we had a lot of the tariff pressures a year ago. So of course, the U.S. would have had a higher price realization than some of the other geographies. Kallum Titchmarsh: Great. And I know they're relatively small portions of the business, but maybe just talk us through in a bit more detail what you've seen in the high-growth areas like bioprocess and semis. And then for those areas, I guess, are you comfortable with the portfolio you have today of products? Or would there be appetite to perhaps offer something broader for the future? Patrick Kaltenbach: Yes. Thanks, Kallum. These hot segments, whether it's semiconductor, battery, GLP-1 and others, these are all low single-digit contributors to our overall sales, but they see really good growth. And of course, our market teams are really focused on solutions for these areas. So I would say we play well in them. If you look at the U.S., as Shawn said, semiconductor definitely is a really good segment, GLP-1s, the whole biopharma segment. If you go to other areas around the world, if you go to, for example, to China, the battery segment is really also back there to very good momentum and also investment in biopharma and GLP-1s. But don't think this is the larger part of our business. Again, the broader part of our business is in pharma, biopharma, in chemical and food and other areas, but these hot segments are important from us from a perspective that we really want to maximize our growth in these areas as well, and we do very strategic investments when it comes to solutions for these end markets and working very, very close with customers whenever they need specific tailored solutions for their segments. For example, we had very good results there, working closely with some of the largest battery manufacturers over the last couple of years to make sure that we develop tailored solutions that really drove significant growth for us in these areas. Elizabeth Koslosky: So first, I guess, maybe touch on the Lab business and what's driving that improvement. Are you starting to see pharma invest more heavily in sort of lab in the loop and automation capabilities as they look to shore up some of their AI strategies? Or would you characterize the improvement in pharma and Lab as just kind of general certainty coming back to the market? Patrick Kaltenbach: Yes. Look, when you look at Lab, I mean, a lot of it is, of course, driven by the innovation we have brought out, not only in terms of automation and digitalization capabilities, but that's a good part of it as well. You got that. I mean, when you think about how pharma companies are automating their experimental setup, they'll use a lot of our equipment together with some of the automation partners that we have, and to automate their experiments and to really drive towards higher throughput. What is essential there is that they also have an informatics platform like LabX that collects all the information and then they can use that on an aggregated level to drive the next experimental conditions, et cetera. But Lab overall is benefiting across the board, not only from automation, but also from the number of new products and new features with the products, innovation that we released over the last years, and it goes almost across the entire value chain in Lab. Because think about the more early research part, we launched a new semi-automatic pipette this year, which has really -- received really well in AutoChem, we just launched a new solution that we think will drive some good growth moving forward. And then on the Lab product categories, we have also launched a lot of new products. So I think there is given that we have also a big exposure to the QA/QC market, that will be a good momentum for us moving forward. Shawn Vadala: Yes. And I think the -- like part of your question was also the uncertainty. Like I think the increased certainty certainly helps, right? Like we hear that a lot in terms of like biopharma generally spending more than they -- where there was a lot of hesitation at the beginning of the year. Elizabeth Koslosky: Great. That's super helpful. And then maybe touch on your service business, how that trended in the quarter and then updated expectations going forward? Patrick Kaltenbach: Yes. Service in the quarter grew -- what was it 9%? Shawn Vadala: It was 9%, organically it was 7%. Patrick Kaltenbach: Organic 7%. So again, really growing faster than our products at the moment, and we're really proud of that. We continue to make really strategic investment -- in our service business, we have still a good opportunity to continue to outgrow the rest of the market, #1. Our service is an important business for us because it drives a lot of customer loyalty. Our Net Promoter Scores are very high in this area. We launched also new capabilities in service. For example, our service engineers have now access to an AI-supported knowledge base where they can basically use all of the internal information that we have regarding earlier service records, about R&D material, application notes, et cetera. So whenever they go out and service a product, they basically can use these AI-supported tools to do best-in-class service, which drives, of course, our first fix ratio a lot and also drives customer loyalty up. There's a lot of things that customers can get, but I say only at MT because we have access to this data. We have access to solutions that none of our competitors have when it comes to servicing instruments that are in the installed base. And there's still a growing opportunity for us moving forward. So I'm very optimistic that services will continue to grow. Last year, we, for the first time, exceeded $1 billion revenues in services, and that's at a high single-digit growth rate. Shawn Vadala: Yes. So to put it in perspective, for the year, it's probably going to be high single digit for the full year. Q3 might be more like mid- to high. But when you step back for the full year, we're very happy with that performance. Michael Polark: I just have one question. My understanding is the U.S. Pharmacopeia had some material revisions that went into effect earlier this year around pharmaceutical weighing requirements. I've seen some analysis that's describing this as quite significant. So -- and I believe the effective date for compliance started in the first quarter of this year. So is this an influence that you would spike out? If so, what sort of activities is it driving at customers? And how is Mettler exposed to such a change? Patrick Kaltenbach: Yes. Thanks. That's a very good point. I mean it's not only the U.S. Pharmacopeia, we have seen already last year and early this year, the revisions of the Japanese Pharmacopeia and the China Pharmacopeia last year, which actually had the same revisions when it comes to weighing regulations, which helped to drive incremental growth. And we are extremely well positioned with our -- exactly with the recently launched portfolio of new Lab balances to help our customers to support them with complying with these regulations. Dan Leonard: Patrick, I would just like to revisit your comments on emerging markets outside of China, that high single-digit growth rate. Can you offer some more color? Is that all volume? Do you have pricing power? Anything to share on service attachment rate and the long tail of emerging regions? Patrick Kaltenbach: Yes, very good question, Dan. Thank you. Yes, we are growing high single digits in these emerging markets outside of China. And of course, if you think about, for example, India has great momentum, if you think also regions outside of Southeast Asia, if you think about Latin America, Mexico, Brazil, et cetera, where we see pretty good growth and also good investments of many companies out there. We -- there is also some reshoring onshoring, but let's say, reshoring ongoing also in these regions, which really helps us to benefit a lot from the growth opportunities across our platform. So this is a play that goes across -- I mean if you think about the end markets, it goes across pharma, but also chemical and chemical also if you think, for example, about investments into the battery segment, where manufacturers have expanded their footprint outside of China into other areas into Asia Pacific. And that comes along with a lot of investment in new instruments but also, of course, related services. I wouldn't say that there's a significant difference in terms of connect rate when it comes to the laboratory instruments outside of -- or in these emerging markets compared to other regions. So that, of course, then also drives an additional incremental revenue opportunity for us moving forward and also recurring revenues. Shawn Vadala: And we also do well on price as well in these markets. It's like I said before, it's very much a global topic for us where the value proposition tends to resonate globally, which is great. Dan Leonard: And then as a follow-up, does the opportunity in these emerging markets just map towards manufacturing GDP by country? Or are there any areas of disproportional opportunity that you would highlight? Shawn Vadala: I think India, I mean, certainly is a standout, right? I mean, at least the last couple of years, if you look at the growth, it's been really, really impressive. It's certainly a geography that we prioritize on. And we just think we have a lot of great opportunity there. And if you look at the underlying -- some of the near-shoring and opportunities with generics, those types of things, there's just a lot of good things on the horizon there. But I mean, all the other areas, too, we differentiate on as we allocate resources and not to repeat them all, but Patrick mentioned a lot of them, but like -- but they're all -- whether they're in Asia, Eastern Europe, Latin, South America, there's a lot of great opportunity. And one of the strengths of Mettler has always been that we have direct sales organizations in these individual countries so that we can really understand the local markets and really have teams that really have that application know-how and work with the local customers, and that really makes a difference. Adam Uhlman: Thanks, Jonathan, and thank you, everybody, for joining us this morning. Please feel free to reach out to me if you have any follow-up questions, and I hope you all have a great weekend. Take care. Before you buy stock in Mettler-Toledo International, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Mettler-Toledo International wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $397,405!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,344,091!* Now, it’s worth noting Stock Advisor’s total average return is 953% — a market-crushing outperformance compared to 214% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of August 7, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Mettler-Toledo (MTD) Q2 2026 Earnings Call Transcript was originally published by The Motley Fool

Mettler-Toledo International Inc. recently reported second-quarter 2026 results showing higher sales of US$1,027.31 million and net income of US$232.90 million, while also appointing MISTRAS Group CEO Natalia Shuman to its Board of Directors effective 3 August 2026. Together with Baron Capital’s decision to increase its long-held position after a recent pullback, these developments point to growing institutional engagement and fresh governance expertise focused on technology-enabled services and asset integrity. Next, we will examine how Shuman’s board appointment could influence Mettler-Toledo’s investment narrative around automation, services, and long-term earnings quality. Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow. To own Mettler-Toledo, you need to believe its precision instruments, software and services can keep deepening their role in regulated pharma and food workflows, even as tariffs, macro uncertainty and slower end markets weigh on visibility. The latest Q2 2026 results, with higher sales and earnings, suggest the near term catalyst remains execution on automation and services, while trade friction and delayed customer replacement cycles continue to look like the key risks. Shuman’s appointment does not materially change those near term drivers. The most relevant recent development is the appointment of MISTRAS Group CEO Natalia Shuman to the Board, which strengthens Mettler-Toledo’s governance bench in technology enabled services and industrial asset integrity. This aligns closely with the company’s push into higher value analytics, automation and recurring service offerings that underpin its main catalyst of increased demand from more regulated, data intensive pharma and food production, even as tariffs and regional demand softness remain in focus. Yet while automation and services are clear positives, investors should also be aware of how elevated and unpredictable global tariffs could... Read the full narrative on Mettler-Toledo International (it's free!) Mettler-Toledo International's narrative projects $4.8 billion revenue and $1.1 billion earnings by 2029. This requires 4.9% yearly revenue growth and roughly a $200 million earnings increase from $905.6 million today. Uncover how Mettler-Toledo International's forecasts yield a $1387 fair value, a 3% downside to its current price. Two fair value estimates from the Simply Wall St Community cluster between US$1,260.89 and US$1,387.09, underscoring how differently individual investors can view Mettler-Toledo’s worth. You can weigh these community views against the tariff and trade risks that could pressure margins and shape the company’s future earnings power. Explore 2 other fair value estimates on Mettler-Toledo International - why the stock might be worth 12% less than the current price! Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts. A great starting point for your Mettler-Toledo International research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision. Our free Mettler-Toledo International research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mettler-Toledo International's overall financial health at a glance. Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters: Find 52 companies with promising cash flow potential yet trading below their fair value. We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them. This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include MTD. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

Mettler-Toledo International MTD reported second-quarter 2026 adjusted earnings of $11.46 per share, which beat the Zacks Consensus Estimate of $10.78 by 6.31%. Adjusted earnings increased 14% year over year.Net sales of $1.03 billion increased 4% year over year but missed the Zacks Consensus Estimate of $1.03 billion by 0.46%. Better-than-expected organic sales growth, including strong demand in China and emerging markets, supported the quarter. On a local-currency basis, MTD's sales increased 3% in the Americas, 4% in Europe and 10% in Asia/Rest of World in the quarter. Excluding acquisitions and one-time tariff refunds to customers, organic local-currency sales increased 4%, including 1% growth in the Americas and 9% growth in Asia/Rest of World.By geography, Americas sales declined to $402 million from $414 million, accounting for 39% of total revenues. Europe sales increased to $294 million from $274 million and represented 29% of revenues, while Asia/Rest of World sales rose to $331 million from $295 million, contributing 32% of total revenues. Mettler-Toledo International, Inc. price-consensus-eps-surprise-chart | Mettler-Toledo International, Inc. Quote Laboratory sales increased to $553 million from $538 million in the prior-year quarter. Industrial sales improved to $418 million from $395 million, while Food Retail revenues increased to $57 million from $51 million.On an organic local-currency basis, Laboratory sales increased 4%, Industrial sales rose 3%, including 4% growth in Core Industrial and 1% growth in Product Inspection, while Food Retail sales climbed 11%. Service revenues increased 9%, or 7% organically.Management noted that China delivered 9% growth, supported by Industrial demand, while emerging markets outside China also posted high-single-digit growth. Improved conditions in biopharma, automation, semiconductor, batteries and food manufacturing markets also aided performance. Adjusted gross profit increased to $625.7 million from $579.9 million. Adjusted gross margin expanded 30 basis points year over year to 59.3%, benefiting from pricing, lower tariff rates, productivity initiatives and volume growth, partly offset by higher transportation costs.Research and development expenses increased to $53 million from $49.3 million. Selling, general and administrative expenses rose to $263.3 million from $247.3 million.Adjusted operating profit increased 9% year over year to $309.3 million. Adjusted operating margin expanded 50 basis points to 29.3%. Reported diluted earnings per share were $11.55 compared with $9.76 in the prior-year quarter. As of June 30, 2026, cash and cash equivalents were $51.4 million compared with $60.5 million as of March 31, 2026. Long-term debt declined sequentially to $2.04 billion from $2.16 billion.Year-to-date adjusted free cash flow totaled $367 million. Management noted that free cash flow was affected by the timing of tax payments, which were $55 million higher than the prior year.The company also increased its planned share repurchases for 2026 to $875 million from the annualized first-half pace of $825 million. Management cautioned that market conditions remain uncertain and could change quickly, but guided for third-quarter 2026 local-currency sales growth of approximately 4%. Adjusted earnings for the third quarter are forecast to be in the range of $12-$12.15 per share, implying 8-9% growth year over year.For 2026, MTD raised its local-currency sales growth outlook to approximately 4-5% from the prior view of approximately 4%, and raised adjusted earnings guidance to $47.15-$47.50 per share, representing growth of 10-11%, from the prior outlook of $46.30-$46.95. MTD currently carries a Zacks Rank #2 (Buy).Some other top-ranked stocks in the broader Zacks Medical sector are Progyny PGNY, Centene CNC and GETINGE GNGBY, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.Shares of Progyny have surged 21.2% year to date. The Zacks Consensus Estimate for Progyny’s 2026 earnings is pegged at $2.04 per share, up by 3.55% over the past 30 days, indicating an increase of 7.94% year over year.Shares of Centene have jumped 51.2% year to date. The Zacks Consensus Estimate for Centene’s 2026 earnings is pegged at $4.71 per share, up 36.13% over the past 30 days, indicating a rise of 126.44% year over year.GETINGE shares have appreciated 5.2% year to date. The Zacks Consensus Estimate for GETINGE’s 2026 earnings is pegged at $1.38 per share, up by 9.52% over the past 30 days, indicating an increase of 20% year over year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Mettler-Toledo International, Inc. (MTD) : Free Stock Analysis Report Centene Corporation (CNC) : Free Stock Analysis Report GETINGE (GNGBY) : Free Stock Analysis Report Progyny, Inc. (PGNY) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

For the quarter ended June 2026, Mettler-Toledo (MTD) reported revenue of $1.03 billion, up 4.5% over the same period last year. EPS came in at $11.46, compared to $10.09 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $1.03 billion, representing a surprise of -0.46%. The company delivered an EPS surprise of +6.31%, with the consensus EPS estimate being $10.78. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Mettler-Toledo performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Net Sales- Products: $753 million compared to the $765.74 million average estimate based on two analysts. The reported number represents a change of +2.6% year over year. Net Sales- Service (Point in Time+Over Time): $274.31 million versus the two-analyst average estimate of $269.74 million. The reported number represents a year-over-year change of +10.2%. Net Sales- Retail: $57.06 million versus the two-analyst average estimate of $52.03 million. The reported number represents a year-over-year change of +12.6%. Net Sales- Industrial: $417.7 million versus $414.65 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +5.9% change. Net Sales- Laboratory: $552.55 million versus the two-analyst average estimate of $562.82 million. The reported number represents a year-over-year change of +2.7%. View all Key Company Metrics for Mettler-Toledo here>>> Shares of Mettler-Toledo have returned +5.5% over the past month versus the Zacks S&P 500 composite's -0.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Mettler-Toledo International, Inc. (MTD) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Interested in Mettler-Toledo International, Inc.? Here are five stocks we like better. Q2 results exceeded expectations: Sales rose 7% in U.S. dollars to $1 billion, while adjusted EPS increased 14% to $11.46. Growth was supported by China and emerging markets, Laboratory and Industrial demand, and the Spinnaker sales program. Margins improved despite mixed conditions: Adjusted operating margin expanded 50 basis points to 29.3%, helped by pricing, productivity and cost savings. China and Asia/rest of world grew 9% organically, while Food Retail and service revenue also posted strong gains. 2026 outlook was raised: Mettler-Toledo now expects 4%–5% local-currency sales growth and adjusted EPS of $47.15–$47.50, representing 10%–11% growth. The company also plans to repurchase $875 million of shares and expects approximately $900 million in free cash flow. Matador’s Results Were Better Than Feared, But 2026 Headwinds Still Matter Mettler-Toledo International (NYSE:MTD) reported second-quarter results that exceeded its prior sales-growth expectations, supported by improving market conditions, particularly in China and other emerging markets, as well as its sales and marketing initiatives. Chief Executive Officer Patrick Kaltenbach said the company’s performance reflected “better-than-expected organic sales growth across our portfolio,” with strong execution of its Spinnaker sales and marketing program and productivity initiatives contributing to adjusted earnings-per-share growth. → Why SK hynix Could Be the Best AI Chip Stock to Buy Now 3 Mid-Cap Energy Firms Analysts See Moving Up to the Big Leagues Second-quarter sales were $1 billion, up 7% in U.S. dollars and 6% in local currency. Acquisitions contributed about 1.5 percentage points of sales growth, while organic local-currency sales increased 4%. The company said its reported results included a one-time $52 million gross benefit from IEEPA tariff refunds, which was recorded in cost of sales. That benefit was partly offset by a $28 million refund to customers that reduced reported net sales by 3%. Management excluded both tariff-refund items from its discussion of adjusted results and guidance. → Microsoft Just Flipped the AI Spending Narrative Overnight 5 Highly Rated Dividends With 50% Upside According to Analysts Organic sales, excluding acquisitions and tariff refunds, increased 1% in the Americas, 4% in Europe and 9% in Asia/rest of world. China also grew 9%, exceeding management’s expectations. Kaltenbach said China’s growth was led by Industrial, which posted double-digit growth in the country. Demand was supported by biopharma, food, batteries and new-energy investments. Laboratory growth in China was more modest, though the company expects further improvement in the second half. → Carrier Earnings Could Send the Stock to a New All-Time High By product area, organic sales in Laboratory increased 4%, while Industrial sales rose 3%. Core Industrial grew 4%, partially offset by 1% growth in Product Inspection. Food Retail sales increased 11%, aided by the timing of project activity, while service revenue rose 9%, or 7% organically. Laboratory growth was broad-based, according to Kaltenbach. Process analytics and bioproduction performed strongly, while laboratory balances and analytical instruments benefited from newer product introductions. The company also cited demand for its LabX software platform and activity in semiconductors, advanced materials and batteries. In Industrial, Mettler-Toledo saw strong demand for automation-related solutions across biopharma, food manufacturing, semiconductors and new energy. Product Inspection growth was modest because of customer-project timing, but Chief Financial Officer Shawn Vadala said the company expects organic growth in that business to improve in the second half. He projected mid-single-digit Product Inspection growth for the third quarter and high-single-digit growth for the full year, including acquisition contributions. Adjusted gross margin was 59.3%, up 30 basis points from a year earlier. Excluding foreign exchange and acquisitions, gross margin expanded about 90 basis points, driven by favorable price realization, lower tariff rates than the prior year, volume growth, productivity initiatives and cost savings. Those benefits were partly offset by higher transportation costs. Adjusted operating profit rose 9% to $309 million, and adjusted operating margin increased 50 basis points to 29.3%. Excluding unfavorable currency, adjusted operating margin increased 100 basis points. Adjusted EPS increased 14% year over year to $11.46. Reported EPS was $11.55, compared with $9.76 in the prior-year quarter. Reported EPS included a net tariff-refund benefit of $0.92, along with $0.26 of purchased intangible amortization, $0.22 of restructuring costs, a $0.04 tax headwind tied to stock-option exercise timing, and a $0.31 acquisition-related charge related to higher earn-out achievements. Year-to-date adjusted free cash flow was $367 million, affected by tax payments that were $55 million higher than the prior year because of timing. The company reported days sales outstanding of 35.6 days and inventory turnover of 4.2 times. Mettler-Toledo raised its 2026 local-currency sales-growth forecast to approximately 4% to 5%, from approximately 4% previously. The revised outlook implies 3% to 4% organic local-currency growth and excludes the tariff-refund effects. Full-year adjusted EPS is projected at $47.15 to $47.50, representing growth of 10% to 11%, or 11% to 12% excluding currency. The prior full-year adjusted EPS outlook called for growth of 8% to 10%. Third-quarter local-currency sales growth is expected to be about 4%, including roughly a 0.5% benefit from acquisitions. Third-quarter adjusted EPS is forecast at $12.00 to $12.15, up 8% to 9%, or 9% to 10% excluding currency. Full-year free cash flow is expected to be approximately $900 million. The company now expects to repurchase $875 million of shares during 2026, compared with an annualized repurchase pace of $825 million in the first half. At recent spot rates, the company expects foreign currency to add about 1% to full-year sales growth but create a slight EPS headwind. Currency is expected to be neutral to third-quarter sales and reduce third-quarter adjusted EPS growth by roughly 1 percentage point. Kaltenbach highlighted emerging markets as a long-term source of growth. Emerging markets outside China accounted for approximately 18% of second-quarter sales, slightly more than the company’s China business, and grew at a high-single-digit rate. Management said those markets have grown at a high-single-digit local-currency average over the past five years. The company cited India, Southeast Asia, Eastern Europe and Latin America as areas of opportunity, including potential benefits from nearshoring investment. Kaltenbach said Mettler-Toledo’s local market organizations, direct sales capabilities, local manufacturing and assembly capabilities in markets such as Mexico, and global data infrastructure position it to pursue growth opportunities. Management also said biopharma activity improved, particularly in process analytics and bioproduction. Kaltenbach said Mettler-Toledo is seeing requests for quotations tied to U.S. reshoring, but characterized the opportunity as still in its early stages. He said more substantial facility investments could extend into 2027 and 2028. While the company acknowledged continued geopolitical uncertainty and volatile conditions in the Middle East, Vadala said Mettler-Toledo has limited exposure to the region and has not observed a related change in customer behavior. The company did not include an escalation of the conflict in its forecast. “We remain focused on capitalizing on our customers’ investments in automation, digitalization, and onshoring around the world,” Kaltenbach said. Mettler-Toledo International Inc is a global manufacturer and distributor of precision instruments and services for laboratory, industrial and food retail applications. The company's product portfolio includes laboratory balances and analytical instruments, industrial weighing systems, process analytics and sensors, metal detection and x-ray inspection equipment, checkweighers, and a range of automated inspection and data-management solutions. Mettler-Toledo also provides software, calibration and lifecycle services intended to support compliance, quality control and operational efficiency across customer facilities. The company serves a broad set of end markets including pharmaceutical and biotech laboratories, chemical and food processors, logistics and manufacturing operations, and retail environments where accurate weighing and inspection are critical. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Mettler-Toledo International Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for July 2026.

This article first appeared on GuruFocus. Release Date: July 31, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Mettler-Toledo International Inc (NYSE:MTD) reported strong Q2 2026 results with better-than-expected organic sales growth of 4%, driven by improved market conditions and the successful execution of its Spinnaker sales and marketing program. The company saw very good growth in China (9%) and emerging markets (high single-digit), which are key strategic growth areas, and it raised its full-year guidance for local currency sales growth to 4% to 5%. Adjusted EPS grew 14% in the quarter, and the company raised its full-year adjusted EPS guidance to $47.15-$47.50, reflecting 10% to 11% growth, driven by strong operational execution and productivity initiatives. The company is seeing improving trends in its biopharma customer base, with strong growth in process analytics and bioproduction, and it is well-positioned to benefit from long-term trends in automation, digitalization, and onshoring investments. The service business continues to be a strong performer, growing 9% (7% organically) in the quarter, and the company is investing in AI-supported tools for its service engineers to drive customer loyalty and further growth. The company's pricing power remains robust, with price realization of approximately 3% in the quarter, exceeding its initial guidance of 2.5%, due to a strong value proposition and innovative product portfolio. The company's guidance for the second half of 2026 appears conservative, as the EPS raise was largely in line with the Q2 beat, suggesting potential moderation in growth expectations despite improving market conditions. Conditions in the Middle East remain volatile, and while the company has limited direct exposure, an escalation of the conflict could impact customer decision-making and is not included in its current forecast. The product inspection business saw modest organic sales growth of 1% in the quarter due to the timing of customer projects, although growth is expected to pick up in the second half of the year. The Americas region saw only 1% organic sales growth, which was partially offset by timing issues in food retail and transportation and logistics project activity, indicating some regional softness. The company faces challenging comparisons in Q3 2026, particularly in core industrial and the Americas, which grew 10% and 9% organically respectively in the prior year, potentially limiting reported growth. The chemical end market, which is under 15% of total sales, remains a cautious area due to its exposure to energy cost fluctuations, despite some recovery in Q2. Warning! GuruFocus has detected 4 Warning Signs with BOM:532978. Is MTD fairly valued? Test your thesis with our free DCF calculator. Q: Can you dive into the acceleration in China? What does the momentum look like there when it comes to pharma versus non-pharma and the consistency you expect in the coming quarters?A: Patrick Kaltenbach (CEO): We are very happy with the 9% growth in Q2, which was led by industrial with double-digit growth, benefiting from core segments like biopharma, food, and hot segments like battery investments. Lab growth was more modest, but we expect continued improvement in the second half from biopharma and academia. Sean Vidala (CFO): We are looking at high single-digit growth for China in Q3 and the full year, with strong momentum in industrial and gradual improvement in lab. Q: Can you unpack the underlying assumptions for the revised back-half guidance by end market and segment?A: Sean Vidala (CFO): For Q3, lab is expected to grow mid-single-digit, core industrial low single-digit (lapping a 10% comp), product inspection mid-single-digit, and retail flat. By region, Americas are guided low to mid-single-digit (lapping a 9% comp), Europe low single-digit, and China high single-digit. For the full year, lab and core industrial are low to mid-single-digit, product inspection high single-digit, and retail low to mid-single-digit. Q: Where did you land on price realization for Q2, and what are you thinking for the back half? Did you recapture any delayed chemical orders?A: Sean Vidala (CFO): Price realization was around 3% in Q2, better than the 2.5% guidance, driven by innovation and value proposition. We implemented additional pricing measures in a few areas with inflationary pressures, guiding to ~2.5% for the second half. Full-year price realization is approaching 3%. Patrick Kaltenbach (CEO): On chemicals, EU results were better in Q2 and recovered, but we remain cautious on the segment due to energy cost exposure. We will have easier comps in the coming quarters. Q: Can you give more details on what drove the reacceleration in lab? What are you hearing from customers on the inflection, and do you think lab can stay in a steady state of mid-single-digits?A: Patrick Kaltenbach (CEO): Lab performance is driven by strong go-to-market strategies, local market teams, and significant innovation. Process analytics is performing extremely well in biopharma, and analytical instruments had a good Q2. The pipette business returned to growth. We expect mid-single-digit growth, with potential upside from an acceleration in China. Our LabX software platform, connecting ~40% of instruments in QA/QC labs, provides a unique competitive advantage. Q: How are margins tracking versus your plan? Any updated view on full-year margin expectations?A: Sean Vidala (CFO): We feel very good about execution on productivity and cost savings initiatives. Q2 operating margin was up 100 basis points excluding currency. For the full year 2026, we expect operating margin to be up 60-70 basis points excluding currency, modestly better than prior expectations. On a reported basis, it would be up slightly in the 10-20 basis point range. Q: The implied Q4 exit rate is a step up from Q3. What gives you confidence in this sequential step up?A: Sean Vidala (CFO): The implied Q4 growth is higher partly due to Q3 having a much more challenging comparison to the prior year, particularly in industrial and the Americas. Sequentials are in line with historical patterns. We feel good about the momentum entering the back half, with strong customer activity and improving end markets like academia and biotech. Q: Can you expand on biopharma momentum? Was it a big step up, and where are you seeing it most? Do you feel early or have you crested?A: Patrick Kaltenbach (CEO): Bioprocessing is a low double-digit percentage of total sales. Pro had really good growth in Q2, especially in the Americas, with good equipment demand from automation providers. We are extremely well-positioned for reshoring, with ~50% of sales into production and ~20% into QA/QC. We see good RFQ activity related to reshoring, but it's still early. Momentum will pick up in the second half and into 2027, with more investment coming in '27 and '28. Q: You beat Q2 EPS by ~$0.70 and raised guidance by ~$0.70. Is the raise just reflecting Q2, or is there conservatism or offsets?A: Sean Vidala (CFO): We are very happy with Q2 results and the momentum. The second-half guidance reflects a little bit of conservatism or moderation, not reflecting anything negative in the business. It helps de-risk concerns around geopolitical issues. We feel generally pretty good going into the second half. Q: How have reshoring conversations trended, and would you expect orders to roll through before year-end?A: Patrick Kaltenbach (CEO): We see activity with RFQs related to reshoring as customers expand manufacturing in the US. Larger factory investments are still to be made, so it's early innings. Pharma/biopharma investments are largely incremental for us, including tank scales and QA/QC lab instrumentation. Momentum has picked up and should carry well into 2027 and 2028. Q: Can you break out which segments and geographies you've been more aggressive on price? Any reason price couldn't sit above the 2% long-term assumption?A: Sean Vidala (CFO): We wouldn't expect to come out with a higher price increase guidance than 2% for the long term. Geographies with higher inflationary pressures, like the US due to tariffs, have higher price realization. We typically do well in most geographies globally. Q: Can you touch on the service business performance and updated expectations?A: Patrick Kaltenbach (CEO): Service grew 9% in Q2 (7% organically), outpacing product growth. We continue to invest strategically, including AI-supported knowledge bases for service engineers, driving customer loyalty and first-fix ratios. We exceeded $1 billion in service revenue last year and expect high single-digit growth for the full year. Sean Vidala (CFO): Q3 might be mid to For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Mettler-Toledo (MTD) came out with quarterly earnings of $11.46 per share, beating the Zacks Consensus Estimate of $10.78 per share. This compares to earnings of $10.09 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +6.31%. A quarter ago, it was expected that this maker of precision instruments would post earnings of $8.7 per share when it actually produced earnings of $8.91, delivering a surprise of +2.41%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Mettler-Toledo, which belongs to the Zacks Medical - Instruments industry, posted revenues of $1.03 billion for the quarter ended June 2026, missing the Zacks Consensus Estimate by 0.46%. This compares to year-ago revenues of $983.22 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Mettler-Toledo shares have lost about 0.4% since the beginning of the year versus the S&P 500's gain of 6.9%. While Mettler-Toledo has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Mettler-Toledo was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $12.20 on $1.08 billion in revenues for the coming quarter and $46.63 on $4.24 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the bottom 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, ClearPoint Neuro, Inc. (CLPT), has yet to report results for the quarter ended June 2026. The results are expected to be released on August 3. This company is expected to post quarterly loss of $0.29 per share in its upcoming report, which represents a year-over-year change of -38.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. ClearPoint Neuro, Inc.'s revenues are expected to be $13 million, up 41% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Mettler-Toledo International, Inc. (MTD) : Free Stock Analysis Report ClearPoint Neuro, Inc. (CLPT) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

COLUMBUS, Ohio, July 30, 2026--(BUSINESS WIRE)--Mettler-Toledo International Inc. (NYSE: MTD) today announced second quarter results for 2026. Provided below are the highlights: Reported sales increased 4% compared with the prior year. In local currency, sales increased 6% excluding a one-time tariff refund to customers. Net earnings per diluted share as reported (EPS) were $11.55, compared with $9.76 in the prior-year period. Adjusted EPS was $11.46, an increase of 14% over the prior-year amount of $10.09. Adjusted EPS is a non-GAAP measure, and a reconciliation to EPS is included on the last page of the attached schedules. Second Quarter Results Patrick Kaltenbach, President and Chief Executive Officer, stated, "Our second quarter results were strong and reflected better than expected organic sales growth across our portfolio, including very good growth in China and emerging markets. Improved market conditions and benefits from our Spinnaker sales and marketing and productivity initiatives resulted in excellent Adjusted EPS growth in the quarter." GAAP Results EPS in the quarter was $11.55, compared with the prior-year amount of $9.76. Compared with the prior year, total reported sales increased 4% to $1.027 billion. By region, reported sales decreased 3% in the Americas and increased 7% in Europe and 12% in Asia/Rest of World. Earnings before taxes amounted to $289.4 million, compared with $248.7 million in the prior year. Non-GAAP Results Adjusted EPS was $11.46, an increase of 14% over the prior-year amount of $10.09. Compared with the prior year, local currency sales increased 6%, or 4% excluding acquisitions, before a one-time tariff refund to customers that reduced sales growth by 3%. By region, local currency sales increased 1% in the Americas, 4% in Europe, and 9% in Asia/Rest of World excluding acquisitions and tariff refunds. Adjusted Operating Profit amounted to $309.3 million, compared with the prior-year amount of $283.3 million. The Company’s non-GAAP results exclude a one-time $52 million benefit from IEEPA tariff refunds that benefited Cost of Sales, as well as a one-time $28 million related refund to customers that reduced Net Sales. Adjusted EPS and Adjusted Operating Profit are non-GAAP measures. Reconciliations to the most comparable GAAP measures are provided in the attached schedules. Six Month Results GAAP Results EPS was $19.87, compared with the prior-year amount of $17.56. Compared with the prior year, total reported sales increased 6% to $1.974 billion. By region, reported sales were flat in the Americas and increased 10% in Europe and 10% in Asia/Rest of World. Earnings before taxes amounted to $499.1 million, compared with $450.6 million in the prior year. Non-GAAP Results Adjusted EPS was $20.35, an increase of 11% over the prior-year amount of $18.27. Compared with the prior year, local currency sales increased 4%, or 3% excluding acquisitions, before a one-time tariff refund to customers that reduced sales growth by 1%. By region, local currency sales were flat in the Americas and increased 3% in Europe and 6% in Asia/Rest of World excluding acquisitions and tariff refunds. Adjusted Operating Profit amounted to $555.6 million, compared with the prior-year amount of $520.0 million. The Company’s non-GAAP results exclude a one-time $52 million benefit from IEEPA tariff refunds that benefited Cost of Sales, as well as a one-time $28 million related refund to customers that reduced Net Sales. Adjusted EPS and Adjusted Operating Profit are non-GAAP measures. Reconciliations to the most comparable GAAP measures are provided in the attached schedules. Outlook Management cautions that market conditions are uncertain and could change quickly. Based on today's assessment, management anticipates local currency sales for the third quarter of 2026 will increase approximately 4%. Adjusted EPS is forecast to be $12.00 to $12.15, a growth rate of 8% to 9%. For the full year 2026, management anticipates local currency sales will increase approximately 4% to 5% excluding tariff refunds to customers. Adjusted EPS is forecast to be in the range of $47.15 to $47.50, representing growth of approximately 10% to 11%. This compares with previous local currency sales growth guidance of approximately 4% and Adjusted EPS guidance of $46.30 to $46.95. The Company does not provide GAAP financial measures on a forward-looking basis because we are unable to predict with reasonable certainty and without unreasonable effort the timing and amount of future restructuring and other non-recurring items. Conclusion Kaltenbach concluded, "Our team remains agile and focused on capturing growth opportunities leveraging our sophisticated Spinnaker program and innovative product portfolio, while benefiting from trends in automation, digitalization, and onshoring investments. I am confident that strong execution of our strategic initiatives will continue to deliver solid financial performance." Other Matters The Company will host a conference call to discuss its quarterly results tomorrow morning (Friday, July 31) at 7:30 a.m. Eastern Time. To listen to a live webcast or replay of the call, visit the investor relations page on the Company’s website at investor.mt.com. The presentation referenced on the conference call will be located on the website prior to the call. METTLER TOLEDO (NYSE: MTD) is a leading global supplier of precision instruments and services. We have strong leadership positions in all of our businesses and believe we hold global number-one market positions in most of them. We are recognized as an innovation leader and our solutions are critical in key R&D, quality control, and manufacturing processes for customers in a wide range of industries including life sciences, food, and chemicals. Our sales and service network is one of the most extensive in the industry. Our products are sold in more than 140 countries and we have a direct presence in approximately 40 countries. With proven growth strategies and a focus on execution, we have achieved a long-term track record of strong financial performance. For more information, please visit www.mt.com. Forward-Looking Statements Disclaimer You should not rely on forward-looking statements to predict our actual results. Our actual results or performance may be materially different than reflected in forward-looking statements because of various risks and uncertainties. You can identify forward-looking statements by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential," or "continue." We make forward-looking statements in this Quarterly Report about future events or our future financial performance, including sales and earnings growth, earnings per share, strategic plans and contingency plans, growth opportunities or economic downturns, our ability to respond to changes in market conditions, planned research and development efforts and product introductions, adequacy of facilities, access to and the costs of raw materials, shipping and supplier costs, gross margins, customer demand, our competitive position, pricing, capital expenditures, cash flow, share repurchases, tax-related matters, the impact of foreign currencies, compliance with laws, effects of acquisitions, the impact of inflation, ongoing developments related to global trade disputes/tariffs, governmental policies, the geopolitical environment, the conflict in Ukraine and continuing instability in the Middle East on our business. Our forward-looking statements may not be accurate or complete, speak only as of the date of this Quarterly Report, and we do not intend to update or revise them in light of actual results. New risks also periodically arise. Please consider the risks and factors that could cause our results to differ materially from what is described in our forward-looking statements, including ongoing developments related to global trade disputes/tariffs, governmental policies, the geopolitical environment, inflation, the conflict in Ukraine and continuing instability in the Middle East. See in particular "Risk Factors" and "Management’s Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the year ended December 31, 2025 and other reports filed with the SEC from time to time. View source version on businesswire.com: https://www.businesswire.com/news/home/20260730448694/en/ Contacts Adam UhlmanHead of Investor RelationsMETTLER TOLEDODirect: [email protected]